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Abstract
Background: Co-occurrence analysis is a technique often applied in text mining, comparative genomics, and promoter
analysis. The methodologies and statistical models used to evaluate the significance of association between co-occurring
entities are quite diverse, however.
Methodology/Principal Findings: We present a general framework for co-occurrence analysis based on a bipartite graph
representation of the data, a novel co-occurrence statistic, and software performing co-occurrence analysis as well as
generation and analysis of co-occurrence networks. We show that the overall stringency of co-occurrence analysis depends
critically on the choice of the null-model used to evaluate the significance of co-occurrence and find that random sampling
from a complete permutation set of the bipartite graph permits co-occurrence analysis with optimal stringency. We show
that the Poisson-binomial distribution is the most natural co-occurrence probability distribution when vertex degrees of the
bipartite graph are variable, which is usually the case. Calculation of Poisson-binomial P-values is difficult, however.
Therefore, we propose a fast bi-binomial approximation for calculation of P-values and show that this statistic is superior to
other measures of association such as the Jaccard coefficient and the uncertainty coefficient. Furthermore, co-occurrence
analysis of more than two entities can be performed using the same statistical model, which leads to increased signal-to-
noise ratios, robustness towards noise, and the identification of implicit relationships between co-occurring entities. Using
NetCutter, we identify a novel protein biosynthesis related set of genes that are frequently coordinately deregulated in
human cancer related gene expression studies. NetCutter is available at http://bio.ifom-ieo-campus.it/NetCutter/).
Conclusion: Our approach can be applied to any set of categorical data where co-occurrence analysis might reveal
functional relationships such as clinical parameters associated with cancer subtypes or SNPs associated with disease
phenotypes. The stringency of our approach is expected to offer an advantage in a variety of applications.
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Introduction
Biological research has experienced a paradigm shift in the last
decade catalyzed by the availability of genome sequences and the
resulting development of high-throughput technologies. The large
data volumes produced by these novel technologies are often
published as supplementary material and/or stored in extensive
data repositories [1]. Functional interpretation of these data is an
ongoing challenge. Co-occurrence analysis, based on the hypoth-
esis that co-occurring entities are functionally linked, is a technique
that has been used in three main areas of biological research:
1. Co-occurrence of genes in fully sequenced genomes.
2. Co-occurrence of words such as gene names, drug names, and
keywords in titles, abstracts, or entire publications.
3. Co-occurrence of transcription factor binding motifs in sets of
co-regulated genes.
Co-occurrence of genes in sequenced genomes relies on the fact
that proteins do not function in isolation and are dependent on
other proteins, either as direct binding partners, or as catalysts of
substrates. Thus, when two proteins significantly co-occur in a
large number of genomes or can be observed as fusion proteins in
a subset of genomes, they are likely to be binding partners or
enzymes needed for a specific metabolic pathway. Examples of
those studies have been reported by [2–7].
Text mining is a quickly evolving field that aims at developing
technologies helping to cope with the functional interpretation of
large volumes of publications. Co-occurrence of gene names in
publication abstracts, entire publications, or other gene-related
databaseshasbeenusedtoderive co-occurrencenetworkswithclear
evidence that edges in those networks are reflecting functionally
relevant relationships [8–11]. Gene names have also been analyzed
for co-occurrence with other entities such as mutations [12],
chemical compounds [13], and disease related keywords [14]. From
the resulting networks, hypotheses about candidate genes involved
in inherited diseases and drug targets can be derived. Clustering of
gene related publications using keywords has been applied to
enhance the quality of gene expression clusters [15,16]. More
general (non gene-centric) approaches try to organize the literature
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keywords, diseases, phenotypes, chemicals, and similar objects of
biomedical research interest [17–21].
Co-occurrence analysis of transcription factor binding motifs
has been carried out in a variety of slightly differing ways in a wide
range of organisms, including humans. [22–33]. The underlying
hypothesis is that co-regulated genes, identified usually by gene
expression studies, should contain specific combinations of
transcription factor binding motifs in their upstream regulatory
regions, the identification of which would allow the reverse-
engineering of transcription regulatory networks [34].
We have recently applied co-occurrence analysis to studying
published gene expression signatures and showed that co-occur-
rence patterns of genes reflect cancer signaling pathways [35].
Although co-occurrence analysis has a respectable history, the
methodologies used in the studies mentioned above could not be
easily applied to studying gene expression signatures. There are
three main reasons that dictated the use of a different approach.
First, gene expression signatures can vary in size by orders of
magnitude. Obviously, the larger a signature the more likely it is to
find two or more genes co-occurring in that signature. Thus, the
significance of co-occurrences must be evaluated in the presence of
considerable heterogeneity of co-occurrence probabilities among
gene lists. As a consequence, the statistics used to evaluate the
significance of co-occurrence events must reflect this heterogeneity.
In particular, it must be based on list-specific co-occurrence
probabilities. Second, in the vast majority of previous studies, co-
occurrence is analyzed for pair-wise combinations of co-occurring
entities. We found that the resulting stringency of this approach is
not adequate for the analysis of published gene expression
signatures [35]. Third, the null-model against which the significance
of co-occurrences is tested does not work well for gene expression
signatures. A common procedure is to use generic randomization of
the entire data set under analysis or to select subsets of data entries
randomly for comparison purposes. However, gene expression
signatures are composed of distinct gene sets and the null-model
must maintain this property, which is not guaranteed using these
approaches. Furthermore, the list-specific nature of co-occurrence
probabilities cannot be dealt with properly.
NetCutter was developed to address these challenges and to
provide a generic tool for generating and analyzing co-occurrence
networks. Although NetCutter has been developed for the analysis
of gene expression signatures, it is based on abstract concepts that
make it applicable to a wide variety of problems. The input is
represented by a bipartite graph that is composed of list-entry pairs,
which are stored in tab-separated text format. Co-occurrence of
entries in lists is analyzed using pair-wise or higher order
combinations of entries. The significance of co-occurrence is tested
using a novel bi-binomial approximation of Poisson-binomial
statistics (which is a binomial distribution with trial specific
probabilities) that handles list-length-heterogeneity properly and
provides a novel measure of association that is found to be superior
to the Jaccard and the uncertainty coefficients. Occurrence
probabilities are obtained from an edge-swapping procedure that
maintains vertex degrees in the underlying bipartite graph and
distinct sets of entries per list. As we shall see below, this procedure
has a number of advantages over other possible null-models and
permits co-occurrence analysis with near maximumstringency. Last
butnot least,NetCutteris equipped witha numberof algorithms for
the identification of network communities, vertex ranking, and
convenience tools needed in the analysis of co-occurrence networks,
or any undirected graph. We illustrate the utility of NetCutter in the
identification of corresponding clusters of genes and publications
from the PubLiME data set. PubLiME (Published Lists of
Microarray Experiments) is a repository of published cancer related
gene expression signatures (http://bio.ifom-ieo-campus.it/Publime).
The concept of cluster correspondence follows from the bipartite
graph representation of the data. Reversing the list-entry order in the
bipartite graph permits identifying communities of entries as well as
communities of lists. We show that communities of publications
corresponding to communities of genes in the PubLiME data set can
be used to generate hypotheses about the putative function of gene
communities.
Results
The bipartite graph model of co-occurrence analysis
Co-occurrence analysis using NetCutter is based on the
abstraction of list-entry pairs. Any entity that co-occurs with some
other entity must be confined to some sort of container where co-
occurrence is observed. For example, in the case of gene name co-
occurrence in PubMed abstracts, the abstract is the container and
the gene names are the co-occurring entities. Similarly, co-
occurrence of transcription factor binding motifs is observed in
gene promoters. The promoters are the containers where motif
entities co-occur. The containers generally host more than one
entity (otherwise co-occurrence would be impossible) and can be
conveniently interpreted as lists. The co-occurring entities are the
list entries. Lists and entries form a bipartite graph with one part of
the graph representing lists and the other part representing entries.
The presence of a given entry in a given list is indicated by an edge
between the corresponding list and entry vertices. It is required that
each entry can be linked to the same list only once. Without loss of
generality, let’s consider genes as entries and PubMedID_listIDs as
lists in the following, unless otherwise specified (Fig. 1A). This
interpretation of lists and entries has been applied in the co-
occurrence analysis of published gene expression signatures [35].
Occurrence probabilities and null-models
A prerequisite for co-occurrence analysis is the availability of
occurrence probabilities of genes per list. The occurrence
probabilities can be derived from randomizing the bipartite graph
and are dependent on the choice of the null-model. A null-model
creates an occurrence probability matrix where the occurrence
probability for each list–gene pair is listed. As a general property of
this matrix, the sum of all matrix elements must equal the number
of edges in the bipartite graph. This is because each edge is linked
to either side of the bipartite graph with certainty and therefore
the sum of occurrence probabilities over all lists (which can be
calculated as the row sum if genes are listed vertically or as the
column sum if genes are listed horizontally) followed by summing
the results over all genes must be 1 for every edge. The number of
matrix elements is given by #genes*#lists and therefore the
average occurrence probability for any null-model must be
#edges/(#genes*#lists). As a consequence, different null-models
will only be distinguished by the way they attribute occurrence
probabilities to vertices with different vertex degrees but not by the
average occurrence probability.
We consider six different strategies to randomize the bipartite
graph. First, we could reconnect all edges of the graph randomly.
The probability of being connected by an edge for a given list-gene
pair is given by (1/#genes)*(1/#lists). Since there are #edges
edges to be reconnected, the occurrence probability for a single
list-gene pair is #edges/(#genes*#lists), i.e. equal to the average
occurrence probability. Thus, this model provides equal occur-
rence probabilities for all gene-list pairs and does not consider
vertex degrees. We call this model the generic randomization (GR)
model in the following.
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the bipartite graph and reconnect them randomly. The occurrence
probability of a gene vertex would be given by (gene vertex
degree)/#lists. The sum of these probabilities over all lists is equal
to the gene vertex degree and the sum of all gene vertex degrees is
equal to the total number of edges. Thus, the sum of all matrix
elements is equal to the number of edges, as required. Since this
model considers gene vertex degrees, we call it the gene vertex
degree (GVD) model.
Third, we disconnect the edges on the gene side of the bipartite
graph and reconnect them randomly. The probability of a list
vertex being connected to a gene would be given by (list vertex
degree)/#genes. The sum of these probabilities over all genes is
equal to the list vertex degree and the sum of all list vertex degrees
is equal to the total number of edges. Again, the sum of all matrix
elements is equal to the total number of edges. Since this model
considers list vertex degrees, we call it the list vertex degree (LVD)
model.
In model four and five, we reconnect edges considering both
gene and list vertex degrees and allow multiple edges between list-
gene pairs. The occurrence probabilities in model four are
calculated according to the binomial distribution. We calculate
the probability of a list-gene pair for being connected as the
cumulative binomial probability of the list-gene pair being chosen
at least once in the process of randomly reconnecting the edges.
This can be achieved by setting the number of trials equal to the
gene vertex degree, the probability of success equal to the list
vertex degree divided by the total number of edges, and the
number of successes equal to 0. The occurrence probability of a
list-gene pair is then given by the complement of this probability.
This model is called the binomial (BN) model. In model five, we
calculate occurrence probabilities according to the hypergeometric
distribution. The number of successes in the sample is equal to 0,
the sample size is equal to the gene vertex degree, the number of
successes in the population is set to the list vertex degree, and the
population size is the total number of edges. Again, the occurrence
probability of a list-gene pair is obtained as the complement of this
probability. We call this model the hypergeometric (HG) model.
Calculating occurrence probabilities in this manner does not
guarantee that the matrix elements add up to the total number of
edges. Therefore, the matrices are normalized such that this
condition is satisfied by multiplying each matrix element with the
factor #edges/(observed matrix sum), which is generally quite
close to 1, however.
In model six, we again consider vertex degrees, but we require
that each list is composed of distinct sets of genes. Thus, multiple
edges are forbidden. This condition is satisfied by applying an
edge-swapping procedure during graph randomization. Edge-
swapping works by randomly choosing two list-gene pairs from the
bipartite graph and prior to performing the edge-swap, a test is
performed to ensure that the two genes are not already linked to
the respective target lists. This procedure is performed a large
number of times. To ensure complete randomization of the graph,
the number of swaps performed should be significantly larger than
the number of edges. After performing R randomizations of the
graph and counting the number of times a gene has been linked to
a particular list, division of this number by R gives the occurrence
probability of a gene in a given list. As will be shown below, edge-
swapping produces occurrence probabilities that closely approx-
imate occurrence probabilities obtained by generating a complete
permutation set of the bipartite graph, counting the number of
times a gene is found part of a list, and dividing this number by the
total number of permutations. In the permutation model, the sum
of occurrence probabilities of a gene over all lists equals the gene
vertex degree (see below) and thus the sum of all matrix elements is
the number of edges. Since permutation sets of bipartite graphs
Figure 1. Bipartite graph data representation and null-models. A) PubMed IDs (PMIDx) and genes (gx) are represented by vertices of a
bipartite graph. An edge indicates that a gene has been reported as differentially regulated in a specific publication. B–D) Occurrence probabilities of
the bipartite graph shown in panel A as determined by six different null-models for PMID1 (B), PMID2 (C) and PMID3 (D): GR - generic randomization,
GVD - gene vertex degree, LVD - list vertex degree, BN - binomial, HG - hypergeometric, ES - edge-swapping. See text for details of different null-
models.
doi:10.1371/journal.pone.0003178.g001
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close approximation and call this model the edge-swapping (ES)
model.
Fig. 1 shows the occurrence probabilities of the different null-
models for the bipartite graph shown in Fig. 1A. The GR model
yields identical occurrence probabilities for all list-gene pairs, which
is equal to the average occurrence probability in all models. In the
other models, the occurrence probabilities deviate to varying extent
from the average occurrence probability as a function of vertex
degrees. In the GVD model, the deviations are a function of gene
vertex degree and in the LVD model the deviations are dependent
on list vertex degrees. In the remaining models, the deviations are
functions of both the gene and the list vertex degrees. In all cases,
larger than average occurrence probabilities are obtained for larger
vertex degrees at the expense of smaller than average occurrence
probabilities for smaller vertex degrees. From these data, it is
difficult to choose the most effective null-model. A hint can be
gleaned from gene1, however. Gene1 is present in all lists.
Therefore, the co-occurrence probability of gene1 with other genes,
which is calculated by multiplying the occurrence probabilities of
gene1 and geneX for every list under study, should depend only on
the occurrence probability of this other gene. In other words, the
occurrence probability of gene1 in all lists should be 1.0. Only two
models satisfy this constraint: The GVD and the ES models. Since
the GVD model does not consider list vertex degrees, it seems that
the ES model is the preferred null-model.
Expected number of co-occurrences
As a general criterion for comparing the effectiveness of
different null-models, we have to compare them for the number
of expected co-occurrences. The most effective null-model will be
the one that maximizes the expected number of co-occurrences. If
the expected number of co-occurrences is larger, an observed
number of co-occurrences in a real bipartite graph will be less
significant and thus such a null-model permits co-occurrence
analysis with higher stringency. The expected number of co-
occurrences depends in an obvious fashion on the list vertex
degree. If pair-wise co-occurrences are considered, the number of
co-occurrences in a list of vertex degree N is given by the binomial
coefficient N over 2. Larger lists will give rise to more co-
occurrences and the number increases quickly with list vertex
degree. The dependency of the expected number of co-
occurrences on the gene vertex degree is less obvious and depends
strongly on the null-model. A gene that is part of a list with vertex
degree N will give rise to N-1 co-occurrences in that list. The null-
model permits calculating the probability to find this gene in a
given list. Thus, the expected number of co-occurrences of a gene
is given by the sum of expected co-occurrences in all lists where for
a single list the expected co-occurrences are given by (Nl21)*pl.N l
is the list vertex degree and pl is the occurrence probability of the
gene in that list as determined by the null-model.
We used the PubLiME data set [35] to calculate the expected
number of co-occurrences with different null-models. The results are
shown in Fig 2A. The expected number of co-occurrences was
calculated for all genes in all lists using all null-models and the sum of
expected co-occurrences per gene is shown as a scatter plot with the
gene vertex degree on the x-axis and the expected number of co-
occurrences on the y-axis. The results in Fig. 2A suggest the following
rankingof null-models:GR,GVD,LVD,BN=HG,ES. TheBN
andtheHGmodelsperforminanessentiallyidenticalway.However,
the ES model is the model that yields the largest estimates of expected
co-occurrences. The results are also in line with the intuitive
expectation that genes with higher vertex degree give rise to more co-
occurrences. However, it can be seen that this is not true for all null-
Figure 2. Properties of different null-models. GR - generic randomization, GVD - gene vertex degree, LVD - list vertex degree, BN - binomial, HG
- hypergeometric, ES - edge-swapping. A) Expected number of co-occurrences in PubLiME data set: scatter plot of gene vertex degree against
expected number of co-occurrences is shown. The expected number of co-occurrences of a gene is calculated as the sum of expected co-occurrences
per list over all lists. The expected number of co-occurrences per list is given by list-vertex degree minus 1 times the occurrence probability of the
gene in that list. B) Number of co-occurrence modules of size 3 present in at least 5 publications as a function of Poisson-binomial Z-score in the
PubLiME data set. C) Signal-to-noise ratio (SNR) calculated as the number of modules in the real bipartite graph divided by the mean number of
modules in 5 randomized bipartite graphs. D) Average occurrence probability of genes with the same vertex degree as a function of gene vertex
degree. E) Average occurrence probability in lists with the same vertex degree as a function of list vertex degree.
doi:10.1371/journal.pone.0003178.g002
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which do not consider gene vertex degrees.
As outlined above, it is expected that the null-model that yields
the highest estimates of expected co-occurrences should permit co-
occurrence analysis with the highest stringency. In Fig. 2B, this
hypothesis is tested directly again using the PubLiME data set
[35]. For all null-models, co-occurrence analysis was carried out
using module size 3 and support 5 (co-occurrence modules must be
present in at least five publications). The choice of these
parameters has been discussed in [35]. The number of co-
occurrence modules was then determined that have a Z-score
higher or equal than the cut-off shown in Fig. 2B. The Z-score is
calculated from the mean and variance of the Poisson-binomial
distribution as shown in the Materials and Methods section and
published in [35]. More details on the probability distribution will
be provided below. The GR and GVD models perform very
poorly and identify large numbers of modules with high Z-scores.
The LVD model performs a little better and approximates the BN
and HG models at higher Z-score cut-offs. The BN and HG
models give essentially identical results. However, the ES model is
the model that yields the fewest number of significant co-
occurrence modules and is thus the most stringent. The increased
stringency of the ES model over the BN and HG models is also
reflected in a higher signal-to-noise ratio calculated as the number
of significant co-occurrence modules in the real bipartite graph
divided by the number of modules found in a randomized bipartite
graph (Fig. 2C).
The reason for the superior stringency of the ES model over all
other models can be explained by examining the average
occurrence probability per gene and list vertex degree. Fig. 2D
and E show the average occurrence probability of genes with the
same gene vertex degree as a function of the gene vertex degree. It
can be seen that the ES model yields higher occurrence probability
estimates for genes with higher vertex degrees as compared to the
BN and HG models. In GR and LVD models, gene vertex degrees
are ignored and occurrence probabilities for genes with large
vertex degree are very small, which is compensated by larger
occurrence probabilities for genes with small vertex degree. The
GVD model is identical to the ES model in this setting. Fig. 2E
shows the average occurrence probability of all lists with the same
vertex degree as a function of list vertex degree. It can be seen that
the ES model provides higher occurrence probability estimates for
large lists as compared to the BN and HG models. In this setting,
the LVD model performs like the ES model while the GR and
GVD models yield small occurrence probabilities for large lists.
Since it has been shown above that long lists and genes with high
vertex degree are responsible for a large part of the total number
of co-occurrences for the most stringent null-models, the null-
model that provides larger occurrence probability estimates for
genes and lists with high vertex degree at the expense of lower
estimates for smaller degrees will be the most stringent because
large occurrence probabilities make co-occurrence more likely and
thus less significant. By these criteria, the ES model is the most
stringent of all models tested.
The ES model as an approximation of the permutation
null-model
The data shown above have revealed that the ES model is the
best of the models tested. One may wonder, however, whether yet
more effective null-models can be found. An obvious choice would
be the permutation model. In the permutation model, a complete
permutation set of the bipartite graph is created such that each list is
composed of distinct sets of genes. The number of graphs where a
gene is present in a given list divided by the total number of
permutations then provides the occurrence probability estimate.
The permutation model is the ideal null-model because it is
exhaustive. The problem is that a complete permutation set of
bipartite graphs of some complexity is very time consuming to
calculate. For example, the simple bipartite graph from Fig. 1A is
part of a permutation set of 455 graphs. The number of
permutations is increasing quickly as the numbers of genes and
lists grow. However, since edge-swapping ensures that gene lists are
composed of distinct sets of genes, each edge-swap produces a graph
that is part of the permutation set of the bipartite graph. Edge-
swapping can thus be viewed as a random sampling procedure from
the permutation set of the bipartite graph. Therefore, occurrence
probability estimatesderived by edge-swappingshouldapproximate
those obtained from the permutation model.
We generated a complete permutation set of the graph shown in
Fig. 1A to verify this hypothesis. The results are shown in Fig. 3.
Fig. 3A shows how the number of possible permutations can be
calculated. Gene1 is present in all lists and does not have an
impact on the total number of permutations. Gene2, having vertex
degree two, is present in two out of three lists in one out of three
possible ways. The remaining genes have vertex degree 1 and can
be freely chosen to fill the empty slots. We can now count exactly
how many times a gene is linked to a list and divide these counts by
455, the size of the permutation set, to obtain exact occurrence
probabilities. These numbers are shown in graphical form in
Fig. 3B and in numerical form in Fig. 3C. Fig. 3B also shows the
occurrence probability estimates obtained by edge-swapping side-
by-side to the exact occurrence probabilities. The graph in Fig. 1A
was subjected to edge-swapping 1000 times and the number of
times a gene was found present in a list was divided by 1000 to
obtain the occurrence probability. At each run, 100 random edge
swaps were performed to ensure complete randomization of the
graph. This procedure was repeated 10 times and the mean and
standard deviation of occurrence probability estimates for each
gene in each list are shown. In all cases, the mean differs from the
real probability by less than two standard deviations, in most cases
by less than one standard deviation. Thus, edge-swapping provides
reliable estimates of exact occurrence probabilities as determined
from a complete permutation set.
As an interesting observation, we provide evidence that
occurrence probabilities are non-linear functions of vertex degrees
in the edge-swapping model. This is illustrated in Fig. 3C. Individual
and average occurrenceprobabilities are shownasa function ofgene
and list vertex degrees. Non-linearity of individual occurrence
probabilities can be verified from the counts table underneath the
plots. However, the average occurrence probability is found to
depend on vertex degrees in a linear fashion instead. This is a
consequence of the fact that occurrence probabilities of a gene over
all lists add up to the gene vertex degree and that the occurrence
probabilities of all genes for a given list add up to the list vertex
degree.Atthesametime,since themoststringentpermutationbased
null-model predicts non-linear dependencies of individual occur-
rence probabilities on vertex degrees, assuming such linearity in
statistical models of co-occurrence will be linked to loss of stringency.
We conclude that the ES null-model is the null-model that
permits co-occurrence analysis with the highest stringency among
the models tested and that it closely approximates occurrence
probabilities derived from an ideal permutation model. The
increased stringency of the ES model over other models is a
consequence of higher occurrence probabilities for genes and list
with high vertex degrees, which are giving rise to a large part of all
co-occurrences in the bipartite graph. Since large occurrence
probabilities make co-occurrence more likely, the analysis becomes
more stringent.
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Co-occurrence analysis can be thought of as a Bernoulli
experiment with a binomial outcome (a given combination of
entries is either present or not present in a given list). Thus, the
Binomial distribution (BD) is a natural choice for judging the
significance of the number of co-occurrences. However, the BD is
defined for a probability of success which is equal in all trials. The
list-specific nature of occurrence probabilities is not compatible
with this condition (analysis of each list represents one trial), which
means that co-occurrence analysis in the presence of list-length-
heterogeneity is better described as a series of Poisson trials, where
the probability of success varies from trial to trial. Therefore, the
significance of co-occurrences must be evaluated using a binomial
distribution with trial-specific probabilities, i.e. the Poisson-
binomial distribution (PBD). The probability of success in a single
Poisson trial can be calculated by multiplying the list-specific
occurrence probabilities for the combination of genes under study.
The number of occurrence probabilities that need to be multiplied
is equal to the module size, i.e. the number of genes whose
combination is studied. An observed number of co-occurrences for
a combination of genes can then be evaluated using the PBD,
which is given by the formula [36]:
PPBD X~i ðÞ ~
X
N
i
  
k~1
P
i
m:m[Ak fg
pm  P
N{i
n:n[Ak fg
1{pn ðÞ
 !
ð18Þ
The structure of this formula is very similar to the structure of the
formula used to calculate the binomial distribution, except that
multiplication with a binomial coefficient is replaced by summation
over individual terms, which makes calculation of P-values using
(18) inefficient (note that equation numbering starts in the Materials
and Methods section). Here, Ak denotes the k
th set of indices of the i
lists where genes are co-occurring (‘‘success’’). There are
N
i
  
possible sets and summation is carried out accordingly. Ak denotes
the set of indices of N2i lists where genes are not co-occurring
(‘‘failure’’). [36] have reported two fast procedures for calculating
exact PBD P-values. However, both procedures work with
probability ratios and suffer from numerical overflow/underflow
problems for large numbers of trials. NetCutter uses two work-
arounds to circumvent this problem. One is based on using Poisson-
binomial Z-scores, which can be calculated very easily instead (see
below). The other relies on a fast approximation procedure for
calculating Poisson-binomial P-values, which we call bi-binomial
approximation (BBA) or bi-binomial distribution (BBD).
Z-scores and P-values of BBD
Given the mean m (1) and variance s
2 (2) of PBD (see Materials
and Methods), the Z-score associated with a given number of co-
occurrences x is obtained as:
Z~
x{m
s
: ð19Þ
Considering the structure of formulae (1) and (2) (Materials and
Methods section), PBD Z-scores can be calculated very easily and
provide a simple estimate of the significance of co-occurrence
modules. However, in contrast to normally distributed Z-scores,
binomial and Poisson-binomial Z-scores do not correspond to the
same P-value for different sets of probabilities of success. To see
this, calculate for example the probability of success in a series of
100 Bernoulli trials with success probability 0.1 and 0.9 for the
expectation of 10 and 90 successes, respectively. The Z-score will
be 0 in both cases but the corresponding cumulative P-values are
0.5832 and 0.5487. Therefore, exact levels of significance cannot
be derived from Z-scores alone. Thus, a fast and reliable
procedure for calculating Poisson-binomial P-values is needed.
The BBD approximation was developed to solve this problem.
The BBD approximation of PBD P-values follows from the
relationship between the variance of PBD and the population
variance of trial-specific probabilities of success. This relationship
is shown in Materials and Methods to be described by (4):
S2~
N   m{s2   
{m2
N2 ð4Þ
This equation shows that there is an inverse linear relationship
between the population variance S
2 of the N trial probabilities and
Figure 3. Edge-swapping as sampling from a complete
bipartite graph permutation set. A) Calculation of the size of the
permutation set of the graph shown in Fig. 1A. B) Precision of edge-
swapping. Occurrence probability estimates are compared to their true
values. See text for details. C) Individual and average occurrence
probabilities are shown as a function of gene (left panel) and list (right
panel) vertex degrees. The exact numbers of occurrences of each gene
in each list are shown at the bottom and have been used to calculate
exact occurrence probabilities. Note that row and column sums are
adding up to vertex degrees. As a consequence, the average occurrence
probability is a linear function of both gene and list vertex degrees.
doi:10.1371/journal.pone.0003178.g003
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2, which means that PBD becomes
increasingly narrow as the variance of trial probabilities grows. It
also shows that, for constant mean m and number of trials N, the
shape of PBD depends only on the variance of trial probabilities.
Therefore, relationship (4) suggests an easy way to approximate
PBD P-values. The P-value can be obtained by constructing a set of
trial probabilities with equal variance as the original set of trial
probabilities, which, however, are not all different. In other words,
the series of Poisson trials can be replaced by two sets of Bernoulli
trials with trial probabilities p1 and p2 constructed such that the
variance is equal to the original set of trial probabilities. This
strategy is illustrated in Fig. 4 and explains why this approximation
is called bi-binomial. The details on how to obtain the values of the
two sets of Bernoulli trial probabilities and the number of trials with
p1 and p2 as probabilities of success are provided in the Materials
and Methods section. The precision of the BBD approximation is
discussed in supplementary material Simulation S1.
In order to evaluate whether BBD P-values as a significance
measure of co-occurrence offer an advantage over other measures
such as the Jaccard coefficient or the uncertainty coefficient, pair-
wise co-occurrence of two genes in 200 lists with and without list-
length-heterogeneity was studied (Fig. 5). Each gene is assumed to
occur in 100 lists. Therefore, the occurrence probabilities of both
genes over all 200 lists must add up to 100, regardless of list-
length-heterogeneity. For simplicity, occurrence probabilities of
both genes are assumed to be equal in any particular list. The co-
Figure 4. Bi-binomial approximation of Poisson-binomial distribution by replacing Poisson trials with two sets of Bernoulli trials. A)
Three sets of 20 trials each with their respective probabilities of success are shown: Poisson trials (black squares), one set of Bernoulli trials with the
average probability of success (grey diamonds), and the two sets of Bernoulli trials used to approximate the Poisson-binomial distribution (black
triangles). B) The probability density functions corresponding to the trials in panel A are shown: BD - binomial distribution calculated from the
average probability of success (grey line), PBD - Poisson-binomial distribution calculated from Poisson trials (black rectangles), BBD – bi-binomial
distribution approximation calculated from the two sets of Bernoulli trials using the formula shown in Materials and Methods (black diamonds). Note
that PBD is in general narrower than BD and that PBD and BBD are overlapping.
doi:10.1371/journal.pone.0003178.g004
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occurrence probability in that list. For all possible co-occurrences
from 0 to 100, the Jaccard and uncertainty coefficients were
calculated as detailed in the Materials and Methods section. In
addition, cumulative BBD P-values were calculated using the co-
occurrence probabilities as trial probabilities. To illustrate the
advantage of BBD over BD as co-occurrence probability
distribution, cumulative BD P-values of a BD with the same
mean as BBD but constant trial probabilities is shown. These trial
probabilities can be obtained by dividing the mean of BBD by the
number of lists.
Three different cases of list-length-heterogeneity are considered
in Fig. 5: No heterogeneity (standard deviation 0), heterogeneity
with standard deviation 0.283 and heterogeneity with standard
deviation 0.401 in the occurrence probabilities. The Jaccard and
uncertainty coefficients are by definition insensitive to list-length-
heterogeneity because differences in co-occurrence probabilities in
a given list cannot be considered in their calculation. This is
because both coefficients are defined by the counts of the four list
classes: both genes absent, both genes present, first gene absent
second gene present, and first gene present second gene absent, i.e.
by the corresponding contingency table, which does not change
with different list-length-heterogeneity. In the absence of list-
length-heterogeneity, the cumulative P-values of BD and BBD
(which are perfectly overlapping as expected) assume 0.5 at 50 co-
occurrences, which corresponds to the expected number of co-
occurrences calculated as (50=100 occurrences per gene/200
lists)^2*200 lists. The uncertainty coefficient is found to be 0 and
the Jaccard coefficient is 0.33333 at that point. When there is
modest list-length-heterogeneity (standard deviation 0.283), the
mean of BBD is shifting to the right. This is because the sum of
squares of varying occurrence probabilities (i.e. the sum of co-
occurrence probabilities used as trial probabilities, which is equal
to the mean of BBD) is always larger than the sum of squares of
constant occurrence probabilities with the same average occur-
rence probability (0.5). The corresponding BD in the presence of
list-length-heterogeneity is obtained by dividing the expected
number of co-occurrences by the total number of lists, which
means assuming equal co-occurrences in all lists. This visualization
is shown to illustrate how BBD (which is narrower than the
corresponding BD) gives rise to a steeper cumulative distribution
of P-values and as a consequence to more significant P-values for
numbers of co-occurrence that are far from the expectation. As the
level of list-length-heterogeneity grows (standard deviation of
occurrence probabilities 0.401), the mean of BBD is shifted even
further to the right and BBD P-values are distributed in a still
steeper fashion as compared to corresponding BD P-values and
the interval of non-significant co-occurrences is shrinking further.
With modest list-length-heterogeneity, the expected number of co-
occurrences is 66, which is associated with a Jaccard coefficient of
0.49 and an uncertainty coefficient of 0.075. In the case of large
list-length-heterogeneity, the expected number of co-occurrences
is 82 with J=0.69 and UC=0.32.
Taken together, these data show that the expected number of
co-occurrences varies strongly with the level of list-length-
heterogeneity and that the expected number of co-occurrences is
associated with different values of UC and J. To complicate
matters further, 66 co-occurrences (J=0.49, UC=0.075) repre-
sent significant positive association (PBBD=0.996) with equal list
lengths, no significant association with modest differences in list
length (PBBD=0.536) and strongly negative association (meaning
one gene excludes the other) with strong list-length-heterogeneity
(PBBD=0.00016). Thus, the same J and UC association measure is
obtained for positive, negative, and absence of association.
Therefore, the meaning of these measures cannot be interpreted
properly in the absence of knowledge about the occurrence
probabilities of the co-occurring entities. Furthermore, the data in
Fig. 5 also show that neither J nor UC can distinguish between
positive and negative association while this is easy with cumulative
BBD P-values: Large P-values mean positive association and low
P-values mean negative association. In summary, we conclude that
BBD provides a novel association measure that offers a number of
advantages over the existing contingency table based association
measures Jaccard coefficient and uncertainty coefficient. The
results in Fig. 5 also show that significance of association depends
critically on the specific distribution of co-occurring entities over
lists of varying length (because this distribution determines the
occurrence probabilities) and that contingency table based
methods (which cannot capture this distribution) should be
avoided in the presence of significant list-length-heterogeneity.
Generation of co-occurrence networks and the
identification of communities
The procedures outlined above allow the identification of
significant co-occurrence modules in any type of bipartite graph.
Three user defined parameters have an impact on the stringency
of co-occurrence analysis: The module size, the support, and the
Z-score/P-value cutoff. The module size determines how many
entries will be tested for co-occurrence, the support sets a lower
boundary on the required number of co-occurrences, and the Z-
score/P-value cutoff sets the significance threshold. In general,
higher module size leads to more stringent co-occurrence analysis
at the cost of computational complexity. The support parameter
allows limiting this complexity by filtering out co-occurrence
modules which co-occur less frequently than required by the
support. The significance cutoff permits adjusting the signal-to-
noise ratio, which is calculated as the number of co-occurrence
modules observed in the real versus a randomized bipartite graph.
Figure 5. Comparison of measures of association. Two genes are
assumed to occur in 100 out of 200 lists with occurrence probabilities
that are constant (standard deviation 0), vary slightly (standard
deviation 0.283) or strongly (standard deviation 0.401) from list to list.
For each possible number of co-occurrences from 0 to 100, the
uncertainty coefficient (UC), the Jaccard coeffcient (J), and the bi-
binomial cumulative distribution function are calculated (BBD). For
comparison purposes, the cumulative distribution function of the
binomial distribution (BD) is calculated from the average co-occurrence
probabilities, which are obtained by multiplying the occurrence
probabilities of the two genes. Note that the expected number of co-
occurrences depends on the variability in occurrence probabilities and
that the same value of J and UC can be associated with positive,
negative, or absence of association.
doi:10.1371/journal.pone.0003178.g005
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analysis has been reported previously for the PubLiME data set
[35] and is illustrated in a simulation study provided as
supplementary material Simulation S1. From the set of significant
co-occurrence modules, a co-occurrence network is generated by
considering each entry a vertex and drawing an edge between any
two vertices, which have been part of the same significant co-
occurrence module [35].
An important question in the analysis of co-occurrence networks
regards the presence of network communities. Communities can
be understood as groups of vertices with the property that the
number of edges running within groups is larger than expected by
chance and that the number of edges running between groups is
lower than expected by chance [37]. This problem of partitioning
a graph is often referred to as the graph-cut problem (hence the
name NetCutter). NetCutter is built on the Java Universal
Network and Graph framework (JUNG) software package
(http://jung.sourceforge.net), which provides algorithms for solv-
ing this problem. In particular, NetCutter implements the
Bicomponent clustering algorithm [38], the Edge-Betweenness
clustering algorithm [39], and the Exact Flow Community
algorithm [40]. Furthermore, there is a clustering tool that is not
part of the JUNG package, namely an algorithm identifying
communities using eigenvectors of the modularity matrix [37].
The code for this algorithm was kindly provided by Mark
Newman in C++ and ported to Java. In addition to these tools,
NetCutter provides a number of convenience functions for the
analysis of co-occurrence networks, such as testing the significance
of lists reporting a set of entries making up a network community,
ranking of vertices, random graph generators for topological
analysis of co-occurrence networks, and others. Details on all
functions are provided in the NetCutter software documentation.
One of the possible applications of NetCutter is illustrated
below. This application is tightly linked to the bipartite graph
representation of the data. Namely, NetCutter can be used to
perform co-occurrence analysis of genes or list derived from the
same bipartite graph. The network communities identified in each
both reflect the same underlying structure of the bipartite graph.
In the case of gene expression signatures stored in PubLiME,
clusters of genes correspond to clusters of publications, which can
reveal possible functions of gene clusters.
Cluster correspondence and association studies
The co-occurrence analysis of the PubLiME data set published
previously [35] identified 5 major network communities of genes
with consistent functional annotations that are deregulated in
cancer related gene expression signatures. This analysis was
performed by considering all genes mentioned in a particular
publication as a single signature, even though they might have
been part of different tables and cluster analyses. Here we present
an advanced analysis of the PubLiME data set where each table
and/or cluster identified in a given publication is considered as a
separate signature. This brings the total number of signatures to be
analyzed to 1015 comprising a total of 7358 differentially
regulated genes derived from 233 publications reporting cancer
related signatures derived from human samples. We use this
analysis to illustrate three major points: First, the set of
communities reported previously is reproduced by this more
fine-grained analysis. Second, the set of gene communities
corresponds to a set of publication communities. Third, associa-
tions between publications and gene communities can be
calculated with higher stringency using the edge-swapping null-
model in conjunction with bi-binomial P-values as compared to
binomial or hypergeometric statistics.
The bipartite graph to be analyzed is composed of PubMe-
dID_listID-gene pairs (see supplementary material Table S1). Co-
occurrence analysis was carried out in two ways: First, gene co-
occurrence was analyzed and communities of co-occurring genes
were defined by edge-betweenness clustering as described in
Materials and Methods. Second, co-occurrence of PubMedID_lis-
tIDs was analyzed. To this end, the order of PubMedID_listID-
gene pairs was reversed to form GENE-PUBMEDID_LISTID
pairs. Thus, the lists in the resulting bipartite graph are formed by
genes and the entries are the PubMedID_listIDs where the genes
are reported as differentially regulated. Occurrence probabilities
for the reversed bipartite graph can be obtained by transposing the
occurrence probability matrix of the original bipartite graph. Since
the gene communities identified in gene co-occurrence analysis
reflect the structure inherent in the bipartite graph (which is not
affected by reversing the list-entry order), co-occurrence analysis of
the reversed bipartite graph will result in PubMedID_listID
communities that reflect the same underlying structure in the
bipartite graph. In other words, PubMedID_listID communities
correspond to gene communities. In less abstract terms, the
PubMedID_listID communities should correspond to sets of
publications that report similar sets of genes as differentially
regulated. The identification of communities of publications can
help the researcher to easily identify publications studying genes in
a gene community that is of interest to the researcher.
The results of both types of co-occurrence analysis are displayed
in Fig. 6. Fig. 6A shows the gene clusters identified. The clusters
are named after significant enrichments of gene categories as
determined by functional category enrichment using DAVID [41].
The P-values shown are Benjamini corrected for multiple testing
as reported by DAVID. The clusters are very similar to the clusters
published previously [35]. There is one new cluster that is strongly
enriched for ribosomal proteins (‘‘protein biosynthesis’’ cluster),
which has not reached significance in our previous analysis. The
‘‘surface antigen’’ cluster contains many genes that had been
reported as part of the ‘‘signal transduction’’ cluster. Altogether,
however, these results strongly support the notion that the gene
clusters in the PubLiME data set can be reproduced by the more
fine-grained analysis that considers sublists in each publication as
separate signatures.
The corresponding clusters of PubMedID_listIDs are shown in
Fig. 6B. There are five clusters, which have been named after their
corresponding gene cluster. Only one cluster (the ‘‘extracellular
matrix-immune response cluster’’) cannot be separated by edge-
betweenness clustering at the point of maximal graph modularity.
To see that this naming is indeed justified, we needed to
investigate how strongly a given PubMedID_listID is associated
with a given gene cluster, i.e. how significant is the overlap of the
genes reported in a gene cluster and the genes reported in a
PubMedID_listID. Binomial or hypergemetric statistics are
generally used to calculate this significance. However, the bipartite
graph model in conjunction with the edge-swapping null-model
offers a more fine-grained approach based on bi-binomial
statistics.
The edge-swapping null-model determines occurrence proba-
bilities in such a way that the number of genes in a given
PubMedID_listID is associated with insignificant P-values in the
context of the complete bipartite graph. However, when a subset
of genes is analyzed, e.g. all the genes that are reported in a
particular list, the P-value associated with the number of genes
contained in this list will likely be highly significant according to
how unlikely it is to obtain all the genes contained in a given list in
a random draw from all genes present in the bipartite graph. Thus,
PubMedID_listID association with a set of genes in the bipartite
Analysis with NetCutter
PLoS ONE | www.plosone.org 9 September 2008 | Volume 3 | Issue 9 | e3178graph model can be calculated in the following way: The set of
genes that is used to analyze association is used to extract a
subgraph from the original bipartite graph where occurrence
probabilities for each gene-PubMedID_listID pair are identical to
those in the original bipartite graph (i.e. they are not recalculated
by edge-swapping). The vertex degree of the PubMedID_listID
vertices in the subgraph indicates the number of genes contained
in each PubMedID_listID overlapping with the set of genes used
to extract the subgraph. From the occurrence probabilities of the
genes in a given PubMedID_listID, the bi-binomial P-value can
then be calculated for every list vertex degree observed in the
subgraph. In Fig. 7, the significance of association of the
PubMedID_listIDs (see Fig. 6B) with the cell cycle cluster of
genes (Fig. 6A) is calculated. For comparison, binomial and
hypergeometric P-values are also shown. It can be seen that the bi-
binomial P-value is larger than the binomial and hypergeometric
P-values, which means that the strength of association is evaluated
in a more stringent manner using BBD statistics (see Discussion for
an explanation of this observation).
The analysis of significant associations between PubMedID_lis-
tIDs and gene clusters now permit answering the question whether
there is correspondence between gene clusters and PubMedID_lis-
tID clusters. The naming of PubMedID_listID clusters shown in
Fig. 6B is based on the number of PubMedID_listID that are
significantly associated with gene clustersshown in Fig. 6A.First, for
eachgene cluster,allthePubMedID_listIDs thatareassociated with
that cluster with more than 95% confidence (i.e. cumulative bi-
binomial P-values.=0.95) were identified. Second, the number of
significant PubMedID_listIDs in each PubMedID_listID cluster
was counted for every gene cluster. The significance of this number
was then calculated using binomial statistics. The results of this
analysis are shown in Table 1. Negative decadic logarithms of the
binomial P-value are displayed. It is apparent that each Pub-
MedID_listID cluster is strongly associated with at least one gene
cluster, except for the ‘‘extracellular matrix-immune response’’
cluster, which is associated with two gene clusters. The strength of
these associations suggests that the PubMedID_listID clusters are
indeed corresponding to the gene clusters and that both the gene
and the PubMedID_listID clusters reflect the structure of the
bipartite graph representing the PubLiME data set.
Details about all the lists analyzed are attached as supplementary
material Table S2. Looking at these lists, some general conclusions
about the gene clusters can be drawn. Cell cycle cluster genes have
been found deregulated in a wide variety of tumor types such as
colon cancer, breast cancer, in biliary tract cancer, pancreatic
cancer, gastric cancer, prostate cancer, T-cell leukemia, glioma,
acute lymphoblastic and myeloblastic leukemias, soft tissue
sarcoma, neuroblastoma, as well as in a number of cellular model
systems in response to different stimuli. Thus, the cell cycle cluster
seems to consist of genes with a general role in oncogenesis. The
surface antigen cluster instead seems to be derived preferentially
from studies on leukemia. The interferon cluster genes are found
deregulated in virus induced pathologies such as papilloma virus
induced cervical cancer, and viral hepatitis. Immune response
Figure 6. Gene and list communities in PubLiME. A) Co-occurrence analysis of the PubLiME data set was carried out as described in Materials
and Methods. Gene communities in the co-occurrence network were identified by edge-betweenness clustering removing four edges corresponding
to maximal graph modularity. Functional gene category enrichment analysis was carried out for community genes using the DAVID database.
Benjamini corrected P-values are shown for the most significant categories. B) List co-occurrence analysis of the PubLiME data set was carried out on
the bipartite graph with reversed list-gene order as described in Materials and Methods. List communities were identified by edge-betweenness
clustering removing 130 edges corresponding to maximal graph modularity. Community names are derived from analyzing the probability of finding
lists significantly enriched for genes in gene communities as part of the list community as described in Materials and Methods.
doi:10.1371/journal.pone.0003178.g006
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tory conditions such as ulcerative colitis, Crohn’s disease, and
Helicobacter pylori infections. Genes of the extracellular matrix
cluster seem to be associated with cancer progression studies and
metastatic potential. For the protein biosynthesis cluster, there are
15 signatures that are significantly enriched for those genes. The
Figure 7. Lists associated with cell cycle cluster. A) Association is calculated as the cumulative bi-binomial probability of observing a given
number of occurrences of an entry of interest in a subset of lists. When the subset of lists to be analyzed for association is derived from a community
of entries, the underlying bipartite graph must be reversed such that entries become lists and vice versa. Occurrence probabilities for the transformed
graph are obtained by transposing the occurrence probability matrix. B) The cumulative P-value of PubLiME publications reporting 37 genes of the
cell cycle community (Figure 6A) is calculated using BBD, binomial and hypergeometric statistics. The lists are sorted by ascending P-value. BBD
statistics are obtained following the scheme shown in panel A. Binomial and hypergeometric statistics are calculated as: Number of success: the
number of cell cycle genes reported by the list. Number of trials: the number of genes reported in the cell cycle cluster. Probability of success: list
length divided by 7358 total genes in the PubLliME data set used to generate the co-occurrence network.
doi:10.1371/journal.pone.0003178.g007
Table 1. Cluster correspondence.
gene cluster\list cluster LC# (size) LC1 (28) LC2 (31) LC3 (8) LC4 (18) LC5 (3)
surface antigen (193 lists) 16 (4.52) 1 (0.01) 0 (0.11) 1 (0.07) 0 (0.36)
protein biosynthesis (15 lists) 2 (2.13) 1 (1.12) 0 (0.95) 1 (1.55) 3 (7.00)
interferon (64 lists) 4 (1.50) 0 (0.06) 8 (8.66) 3 (1.57) 0 (0.76)
cell cycle (122 lists) 0 (0.01) 22 (11.51) 0 (0.21) 0 (0.05) 0 (0.52)
extracelullar matrix (102 lists) 1 (0.11) 1 (0.09) 0 (0.26) 14 (9.36) 0 (0.58)
immune response (57 lists) 2 (0.68) 2 (0.60) 1 (1.13) 10 (8.32) 0 (0.81)
For every list cluster (LC), the number of lists was determined that are significantly (PBBD.=0.95) enriched for genes that are part of gene clusters. The significance of
this number was evaluated using binomial statistics: #success – enriched lists in list cluster, #trials – number of lists reporting genes in gene cluster (e.g. 122 for cell
cycle cluster), probability of success: size of list cluster divided by total number of lists (e.g. 31/1015 for LC2). The final P-value is obtained as 1 minus the cumulative
binomial P-value. The negative decadic logarithm of the final P-value is shown in parentheses.
doi:10.1371/journal.pone.0003178.t001
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atic cancer, soft tissue sarcoma, lung carcinoma, breast carcinoma,
prostate carcinoma, multiple myeloma, and lymphocytic leukemia.
The genes are also found deregulated in response to DNA damage.
Although the number of signatures is limited, the variation in
conditions where the genes are deregulated is compatible with the
hypothesis that protein biosynthesis genes, as cell cycle genes, are
deregulated in many cancer types, which might reflect the general
property of cancer cells to divide and grow in an uncontrolled
fashion.
Discussion
Here we have investigated basic aspects of co-occurrence
analysis and present a software tool, NetCutter, which can be used
to identify and analyze generic co-occurrence networks. In
NetCutter, a co-occurrence data set is represented as a bipartite
graph with one part representing lists and the other part list entries
whose co-occurrence patterns are studied. The bipartite graph
representation of co-occurrence data sets allows the efficacy of
different null-models to be tested systematically. We have shown
that an edge-swapping procedure used to randomize the bipartite
graph generates a null-model that allows co-occurrence analysis
with the highest stringency. The other null-models tested here tend
to underestimate occurrence probabilities of entries per list for lists
and genes with high vertex degrees, i.e. for lists and genes where
most co-occurrences are observed. As a result, co-occurrences are
judged more significant than they really are.
Co-occurrence data sets with exactly equal lists lengths are likely
to be the exception from the rule. It can be assumed that some list-
length-heterogeneity will be present in most circumstances. An
important consequence of list-length-heterogeneity regards the co-
occurrence probability distribution used to evaluate the signifi-
cance of the observed number of co-occurrences. Co-occurrence
analysis in the presence of list-length-heterogeneity is best
performed using the Poisson-binomial distribution (a binomial
distribution with trial specific probabilities). However, calculating
Poisson-binomial P-values for large numbers of lists is difficult
using existing procedures [36]. We have presented an approxi-
mation to the Poisson-binomial distribution, called bi-binomial
distribution, which is based on replacing the set of Poisson trials by
two sets of Bernoulli trials. The resulting distribution reproduces
the Poisson-binomial distribution nearly exactly and its P-values
can be calculated with ease even for thousands of lists (see also
supplementary material Simulation S1 for details on the precision
of BBD). Importantly, BBD provides a novel measure of
association, which is shown to be superior to existing measures
such as the Jaccard coefficient and the uncertainty coefficient,
whose values cannot be interpreted properly in the absence of
knowledge about the occurrence probabilities of co-occurring
entities.
It is worth noting that Poisson-binomial Z-scores are distin-
guished from Gaussian Z-scores by the fact that they do not
correspond to the same P-value for different PBDs, BBDs, and
even BDs. This is because the Z-score is an explicit part of the
function defining the normal probability density while it is not part
of the definitions of BD, PBD, and BBD densities. As a
consequence, the simple Poisson-binomial Z-score based approach
to evaluating significance of co-occurrence must be complemented
with the BBD to approximate Poisson-binomial P-values in order
to enable multiple testing corrections and to allow calculation of
confidence levels in association studies precisely. However,
NetCutter is equipped with a bipartite graph randomization tool
that permits measuring the number of false positives due to
multiple testing directly by comparing the number of significant
co-occurrence modules in the real bipartite graph to the
corresponding number in a randomized version thereof. Ran-
domization is performed by edge-swapping in order to preserve
vertex degrees. The resulting signal-to-noise ratios that are plotted
for each Z-score/P-value cutoff provide a highly reliable and
visually intuitive defense mechanism against false positives (see also
supplementary material Simulation S1).
In the vast majority of co-occurrence studies, pair-wise co-
occurrences have been analyzed using different statistical models.
We have observed that the stringency of pair-wise co-occurrence
analysis is far below the stringency of co-occurrence analysis using
higher order combinations of co-occurring entities [35]. In
NetCutter, co-occurrence analysis is preceded by occurrence
analysis, i.e. the occurrence probability of each entry in each list is
determined. Starting from occurrence probabilities, co-occurrence
probabilities for any size of co-occurrence modules under study
can be obtained by multiplying the respective list-specific
occurrence probabilities. Given the list-specific co-occurrence
probabilities, bi-binomial P-values are then calculated in exactly
the same way for any module size. As a consequence, NetCutter
can perform co-occurrence analysis for higher order combinations
of co-occurring entries (i.e. larger module sizes) using the same
statistical model. One of the benefits of using higher module sizes
is robustness of the analyses in the presence of noise. This is
because each edge in the resulting co-occurrence network is
evaluated many times since every pair of co-occurring entries can
be part of many higher order co-occurrence modules [35].
Another advantage is that implicit relationships between entries,
which have never occurred together [18], can be derived as a
natural by-product of using module sizes larger than 2. As shown
in a simulation study (supplementary material Simulation S1), the
result is a dramatic reduction of misclassifications at higher
module sizes.
NetCutter can be used to calculate the strength of association
between a subset of entries and lists reporting those entries. In this
case, the analysis is performed on a subgraph of the original
bipartite graph. The subgraph can correspond to communities of
entries in the co-occurrence network, or any set of entries of
interest. NetCutter will then calculate the significance of observing
a given number of occurrences of an entry in the user defined
subset of lists using bi-binomal statistics. This analysis mode
corresponds to association studies with the advantage that the
structure of the underlying bipartite graph (i.e. list length
heterogeneity) is considered and handled appropriately using the
bi-binomial distribution. As a consequence, association studies can
be performed with higher stringency.
This result can be understood by examining the occurrence
probability matrix that is implicitly assumed in performing binomial
orhypergeometric testsforthe significance ofoverlaps. Inboth tests,
a gene is assumed to have an equal opportunity to be present in a
list.Therefore,theprobabilityofsuccess fora genetobepart ofa list
is given by the list vertex degree divided by the total number of
genes. In other words, both tests are implicitly based on the list
vertex degree model, which has been shown previously to
underestimate the occurrence probability and the expected number
of co-occurrences for genes with high vertex degree (see Fig. 2A).
Since the BBD P-values are calculated from the ES-model, which
assigns higher occurrence probabilities to genes with higher vertex
degree and more expected co-occurrences, the observed number of
overlaps between a set of genes of interest and the content of a given
list (which can be viewed as co-occurrence of the overlapping genes
in that list) will be judgedlesssignificant when the overlapping genes
are of high vertex degree (and vice versa when the overlapping
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hypergeometric tests. Since the BBD P-values are derived from the
moststringentESnull-model,BBDP-values providea morereliable
estimate for the significance of overlap.
Co-occurrence analysis of data represented as bipartite graphs
permits visualizing the structure of the bipartite graph either as
communities of list entries (genes) or as communities of lists
(PubMedID_ListID) in co-occurrence networks. We have ana-
lyzed the PubLiME data set for the presence of corresponding
gene and list clusters. In addition to previously published clusters
of genes, we describe a novel gene cluster that is composed of
protein biosynthesis associated genes [35]. We found that the
corresponding clusters of PubMedID_ListID (gene expression
signatures) are in general strongly enriched for genes reported in
the corresponding gene cluster and that interrogation of
corresponding clusters can be used to deduct hypotheses about
the putative function of gene clusters.
In addition to co-occurrence analysis, NetCutter offers a
number of tools for the analysis of co-occurrence networks, or
any undirected graph. In particular, community identification is
supported by four different community identification algorithms.
NetCutter also offers a range of convenience functions that are of
help in network analysis. Worthy of mentioning are the random
graph generators that can provide control graphs for topological
studies. The complete set of options is described in the software
documentation.
In summary, we present a general framework for co-occurrence
analysis with many potential applications. We illustrate a number
of advantages of using the bipartite graph representation of data
and the associated statistics. In particular, the identification of
corresponding clusters permits the identification of functional
subunits such as gene clusters on the one hand, and the generation
of hypotheses about the function of those units by analyzing the
corresponding list clusters on the other hand. Future developments
will be directed towards the analysis of data sets that are
considerably larger than the data sets analyzed so far. For
example, co-occurrence analysis might be of interest for the
analysis of single nucleotide polymorphism (SNP) data sets and
association studies of genome variability with disease. Each patient
is characterized by a specific range of SNPs. Co-occurrence
patterns of patients according to their SNPs could be compared to
clinical parameters with the aim of identifying genomic regions
associated with disease. The increased stringency of association
studies offered by NetCutter may be of use in the analysis of
polygenic diseases where conventional methods fail. For being
useful in this setting, NetCutter must be capable of analyzing
bipartite graphs with millions instead of thousands of vertices.
Materials and Methods
Implementation of NetCutter
NetCutter is written in Java using NetBeans6 software (http://
www.netbeans.info/) and tested on the Java Runtime environment
1.6.0.0. on a Windows XP Professional computer. The Java
Runtime environment, which can be downloaded from http://
java.sun.com/, must be installed on a computer that is intended to
run NetCutter. NetCutter is provided as a single jar file and should
run by double clicking the jar file, provided that the Java runtime
environment is properly installed. NetCutter makes use of the
following software packages and classes: JUNG version 1.3
(http://jung.sourceforge.net/download.html), Apache Jakarta
Commons Collections 3.1 (http://jakarta.apache.org/commons/
collections/), Cern Colt Scientific Library 1.2.0 (http://dsd.lbl.
gov/,hoschek/colt/), Xerces (http://xerces.apache.org/xerces2-
j/index.html), Jama (http://math.nist.gov/javanumerics/jama/),
Netlib Java LAPACK (http://www.netlib.org/lapack/), JFree-
Chart (http://www.jfree.org/jfreechart/), partition.java (http://
astro.u-strasbg.fr/,fmurtagh/mda-sw/java/partition.java).
Bi-binomial approximation of Poisson-binomial
distribution
The Poisson-binomial distribution (binomial distribution with
trial specific probabilities) has recently been proposed as a statistic
that properly handles largely differing sizes of gene expression
signatures in meta-analysis of gene expression data [35]. Z-scores
have been used to estimate the significance of co-occurrence
because P-value calculation is cumbersome and error prone. Two
methods reported by [36] suffer from numerical overflow/
underflow problems when large numbers of Poisson trials with
probabilities deviating significantly from 0.5 are being analyzed.
Therefore, we propose a fast approximation of P-values based on a
bi-binomial distribution. The bi-binomial distribution is a special
case of the Poisson-binomial distribution where the probability of
success can assume only two values. In order to achieve a good
approximation of the underlying Poisson-binomial distribution,
the values of these two probabilities and the number of trials where
they are assumed must be determined carefully. As is shown in the
following, the values of the two trial probabilities and their number
of occurrences follow from the formula used to calculate the
variance of the Poisson-binomial distribution and from the
formula yielding the population variance of trial probabilities of
the Poisson-binomial distribution to be approximated.
The mean m and the variance s
2 of the Poisson-binomial
distribution are given by equation (1) and (2), respectively.
m~
X N
i~1
pi ð1Þ
s2~
X N
i~1
pi{
X N
i~1
p2
i ð2Þ
pi is the trial-specific probability of success and N is the total
number of trials. For the sake of completeness, a formal proof of
equation (1) is reported as supplementary material Proof S1 and
the proof of equation (2) can be obtained in an analogous fashion.
The population variance S
2 of trial probabilities pi is given by
equation (3).
S2~
N1
P N
i~0
p2
i {
P N
i~0
pi
   2
N2 ð3Þ
Rearranging equation (3) considering (1) and (2) leads to (4) and
(5), where pa denotes the average trial probability of success and qa
its complement.
S2~
N1 m{s2   
{m2
N2 ð4Þ
S2~pa{p2
a{
s2
N
~paqa{
s2
N
ð5Þ
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and N2 times during the Poisson trials, respectively. Thus, N1 and
N2 add up to N.
N~N1zN2 ð6Þ
Considering (1), the average trial probability pa can then be
obtained from (7).
pa~
m
N
~
N1
N
p1z
N2
N
p2 ð7Þ
Using (7), p1 can thus be calculated as (8).
p1~
N   pa{N2   p2
N1
ð8Þ
Similarly, considering (2), the variance s
2 is given by (9).
s2~N1p1zN2p2{N1p2
1{N2p2
2 ð9Þ
Substituting p1 in (9) using (8) followed by substituting s
2 in (5)
by (9) leads to a quadratic equation for p2 as a function of pa, N,
and S
2, as shown in equation (10).
p2
2{2pap2zp2
a{
N1
N2
S2~0 ð10Þ
The solution to (10) is given by (11).
p1,2~pa+
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N1
N2
S2
r
: ð11Þ
Setting p2 to
p2~paz
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N1
N2
S2
r
ð12Þ
p1 can be obtained from (8) and shown to be given by formula (13):
p1~pa{
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N2
N1
S2
r
ð13Þ
Choosing p2 as
p2~pa{
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N1
N2
S2
r
ð12aÞ
leads to p1
p1~paz
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N2
N1
S2
r
ð13aÞ
Comparing (13a) to (12) and (12a) to (13), it can be seen that the
formulae are identical except for the fact that N1 and N2 are
reversed. Since the assignment of which set of trials is called N1
and which set of trials is called N2 is completely arbitrary, we can
limit the remaining analysis on (12) and (13) without loss of
generality.
Note that (12) and (13) do not guarantee that p1 and p2 are
always confined between 0 and 1 for any combination of N1 and
N2. While probabilities smaller than 0 or bigger than 1 would still
result in a distribution with the same overall variance as the
original distribution, P-value calculation will be imprecise because
the tails of the distribution will deviate significantly from the
original distribution. Thus, we need to define the values N1 and N2
in such a way that p2,=1 and p1.=0. This can be achieved by
evaluating (12) and (13).
Evaluating (12) for the condition that p2,=1, solving the
resulting inequality for N2, and considering (5), which relates S
2
and s
2, we obtain (14).
N2ƒ
m2
m{s2 ð14Þ
Similarly, evaluating (13) for the condition p1.=0, solving the
resulting inequality for N2, considering (5), which relates S
2 and s
2,
and defining mf the expected number of failures as N*(12pa) (15),
mf~N1 1{pa ðÞ ~Nqa ð15Þ
we obtain (16)
N2§
m1mf{Ns2
mf{s2 ð16Þ
The meaning of these boundaries is best illustrated by
considering a Poisson-binomial distribution whose variance is 0,
i.e. that assumes 1 at X=m and 0 otherwise. In this case (14)
requires N2,=m while (16) requires N2.=m. These conditions
can only be fulfilled contemporaneously when N2 is set to m.
Intuitively, this means that there are m trials with probability of
success 1 and N2m trials with probability of 0, resulting in a
Poisson-binomial distribution with variance s
2=0 and mean m.
When s
2 is larger than 0, the choice of N1 and N2 is more flexible.
However, since the choice of N2=m is valid for all possible values
of s
2, this is how NetCutter determines N1 and N2. When m is not
an integer, N2 is set to the integer closest to m.
Having determined p2 (12) and p1 (13) as well a N1 and N2 (14,
16, 6), we can now calculate the bi-binomial approximation of the
Poisson-binomial distribution in a fashion that is very similar to
calculate the binomial P-value. With q1=12p1 and q2=12p2 we
obtain:
PX ~i ðÞ ~
X i
j~0
N1
j
  
N2
i{j
  
p
j
1p
i{j
2 q
N1{j
1 q
N2{izj
2 ð17Þ
The summation is necessary because i successes can be obtained
from any combination of jp 1 and i2jp 2 trials, where j can assume
any value from 0 to i.
Calculating Jaccard and uncertainty coefficients
For the purpose of comparing the efficacy of the bi-binomial
distribution as a significance measure of co-occurrence, Jaccard
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association) were calculated using the formulae:
J~
A\B
A\BzB\AzA\B
The Jaccard coefficient J is calculated as the number of times A
and B occur together divided by the number of times A occurs
without B plus the number of times B occurs without A plus the
number of times A and B occur together [42].
The uncertainty coefficient [42] is calculated as:
UC~
21 HA ðÞ zHB ðÞ {HA \B ðÞ ðÞ
HA ðÞ zHB ðÞ
HA ðÞ ~{
X 2
i~1
ni
N
ln
ni
N
  
HB ðÞ ~{
X 2
j~1
nj
N
ln
nj
N
  
HA ,B ðÞ ~{
X 2
i~1
X 2
j~1
nij
N
ln
nij
N
  
H is the entropy associated with A, B,a n dAB.F o rA,t h ee n t r o p yi s
calculated from the probabilities of A occurring inn1 out of N lists (n1/
N)a n dA not occurring in n2 out of N lists (n2/N). Analogous
calculations lead to the entropy associated with B. For H(A,B), the
probabilities of AoccurringwithoutB,Boccurring without A,Aand B
occurring together, and neither Anor Boccurring in the lists are used.
Co-occurrence analysis of the PubLiME data set
The bipartite graph to be analyzed is composed of 27619
PubMedID_listID-gene pairs (see supplementary material Table
S1). Edge-swapping (1000 simulations, see above) was used to
determine occurrence probabilities and gene co-occurrence was
analyzed using module size 3 (co-occurrence of three genes), bi-
binomial Z-score cutoff 6, bi-binomial P-value cutoff 1.0E-5, and
support 5. Supplementary material Simulation S1 provides details
on why module size 3 is chosen. The support parameter ensures
that each 3-gene co-occurrence module is present in at least 5
signatures. We identified 1654 significant modules in the test data
compared to 5 modules in a randomized bipartite graph,
corresponding to a signal-to-noise ratio of 331. The co-occurrence
network was generated from the significant co-occurrence modules
by drawing an edge between each pair wise combination of genes
that are part of the same co-occurrence module. Gene
communities were identified in this network by edge-betweenness
clustering removing 4 edges, which resulted in a maximal network
modularity of 0.63. Modularity is calculated as described by [43].
For the identification of PubMedID_listID clusters, the Pub-
MedID_listID-gene pairs in the original bipartite graph were
reversed to form gene-PubMedID_listID pairs. Occurrence proba-
bilities were obtained by transposing the original occurrence
probability matrix determined by edge-swapping as described
above. PubMedID_listID co-occurrence was analyzed using module
size 5, Z-score cutoff 6, bi-binomial P-value cutoff 1.0E-5, and
support 3. Please note that the choice of these parameters is dictated
by the parameters used in gene co-occurrence analysis. The reversal
of the bipartite graph necessitates the support parameter used in
gene co-occurrence analysis (5) to be used as module size in
PubMedID_listID co-occurrence analysis and the module size used
in gene co-occurrence analysis (3) to be used as the support
parameter in PubMedID_listID co-occurrence analysis if the scope
of the analysis is the identification of PubMedID_listID clusters that
correspond to gene clusters identifiedbefore. The significancecutoffs
remain unchanged. PubMedID_listID co-occurrence analysis re-
vealed 448 significant co-occurrence modules in the real bipartite
graph and 6 significant co-occurrence modules in the randomized
bipartite graphwith a signal-to-noise ratioof 75. Communities inthe
resulting co-occurrence network were identified by edge-between-
ness clustering removing 130 edges. The resulting maximal network
modularity was found to be 0.47.
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